2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD73

CD73

ecto-5′-nucleotidase, NT5E

CD73

Related Products

PDF 0.28 MB

CD73 (Ecto-5′-nucleotidase) is a 70-kD glycosylphosphatidyl inositol (GPI)-anchored cell surface protein encoded by the NT5E gene that plays a crucial role in switching on adenosinergic signaling. CD73 is an ectonucleotidase which catalyzes the terminal step in extracellular adenine nucleotide breakdown: the conversion of AMP to adenosine. Adenosine, which binds to a discrete family of cell surface receptors to initiate intracellular signaling cascades, has been shown to be anti-inflammatory and vasorelaxant.

CD73 has both enzymatic and non-enzymatic functions in cells: as a nucleotidase, CD73 catalyzes the hydrolysis of AMP into adenosine and phosphate, and CD73-generated adenosine plays an important role in tumor immunoescape; moreover, CD73 also functions as a signal and adhesive molecule that can regulate cell interaction with extracellular matrix components, such as laminin and fibronectin, to mediate the invasive and metastatic properties of cancers. Both the enzymatic and non-enzymatic functions of CD73 are involved in cancer-associated processes and are not completely independent of each other. There is ample evidence to show that CD73 is a key regulatory molecule in cancer development and is overexpressed in many cancers, including leukemia, glioblastoma, melanoma, ovarian cancer, esophageal cancer, prostate cancer and breast cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-125286
    AB-680
    		Inhibitor 99.71%
    AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.
    AB-680
  • HY-P99039
    Oleclumab
    		Inhibitor 99.90%
    Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity.
    Oleclumab
  • HY-100747
    PSB-12379
    		Inhibitor 99.54%
    PSB-12379, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).
    PSB-12379
  • HY-P99181
    Mupadolimab
    		Inhibitor 99.43%
    Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells.
    Mupadolimab
  • HY-112502C
    MethADP triammonium
    		Inhibitor 99.03%
    MethADP (Adenosine 5'-(α,β-methylene)diphosphate) triammonium is a CD73 inhibitor. MethADP can be used for the research of ATP-adenosine pathway.
    MethADP triammonium
  • HY-162918
    CD73-IN-17
    		Inhibitor
    CD73-IN-17 (compound 19) is a CD73 inhibitor with IC50 of 0.1 μM for hCD73. CD73-IN-17 can be used in anti-cancer research.
    CD73-IN-17
  • HY-161774
    ST80
    		Inhibitor
    ST80 is an inhibitor for interaction of OTUD4 and CD73. ST80 decreases CD73 protein level, increases CD73 protein turnover, reduces immune evasion of tumor cells, and thus exhibits antitumor efficacy against immunosuppressive triple-negative breast cancer (TNBC).
    ST80
  • HY-P990771
    Uprevstobart
    Uprevstobart is an anti-NT5E human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Uprevstobart
  • HY-P99169
    Uliledlimab
    		Inhibitor
    Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer.
    Uliledlimab
  • HY-112502
    MethADP
    		Inhibitor ≥99.0%
    MethADP is a specific CD73 inhibitor.
    MethADP
  • HY-136978
    OP-5244
    		Inhibitor 99.07%
    OP-5244 is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.
    OP-5244
  • HY-137246
    CD73-IN-3
    		Inhibitor 99.89%
    CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research.
    CD73-IN-3
  • HY-103695
    CD73-IN-1
    		Inhibitor 99.46%
    CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.
    CD73-IN-1
  • HY-145334
    CD73-IN-5
    		Inhibitor 98.14%
    CD73-IN-5 is a potent and selective non-nucleotide small molecule inhibitor of CD73 (IC50 = 19 nM).
    CD73-IN-5
  • HY-131967
    CD73-IN-4
    		Inhibitor 99.21%
    CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology.
    CD73-IN-4
  • HY-136978A
    OP-5244 sodium
    		Inhibitor 99.87%
    OP-5244 sodium is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 sodium reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.
    OP-5244 sodium
  • HY-125286A
    AB-680 ammonium
    		Inhibitor
    AB-680 ammonium is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.
    AB-680 ammonium
  • HY-112502B
    MethADP sodium
    		Inhibitor
    MethADP (sodium salt) (Adenosine 5'-(α,β-methylene)diphosphate (sodium)) is a specific CD73 inhibitor.
    MethADP sodium
  • HY-160696
    ORIC-533
    		Inhibitor
    ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment.
    ORIC-533
  • HY-P99865
    Dresbuxelimab
    Dresbuxelimab (AK-119) is an IgG-κ monoclonal antibody targeting CD73. The expression system is usually CHO (Chinese Hamster Ovary) cells.
    Dresbuxelimab
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity